Interleukin Biomarkers for Histology-Aligned Activity in Inflammatory Bowel Disease

Supplementary material for a systematic review evaluating interleukin signatures as biomarkers in inflammatory bowel disease. The review, authored by figshare admin karger and last updated in April 2026, synthesized evidence from 64 adult cohorts published between 1995 and 2025. It assesses the diagnostic and prognostic performance of six interleukins against validated histological indices.

Use Cases

• Identify candidate serum biomarkers for histological activity based on reported AUC values for IL-6 and IL-23.
• Investigate tissue-level inflammatory signatures based on the alignment of IL-23 and IL-17A with neutrophil activity and crypt injury.
• Assess prognostic value for remission stability based on the inverse correlation of IL-10 with disease activity.
• Compare interleukin profiles with standard biomarkers like CRP and fecal calprotectin for precision medicine strategies.

Strengths

• Systematic review methodology included 64 adult cohorts, providing a broad evidence base.
• Risk of bias was assessed using standardized tools (QUADAS-2 and QUIPS).
• The certainty of evidence was graded using the GRADE framework.

Limitations

• The dataset consists of supplementary PDF/DOCX files (144.5 KB); the underlying raw data or a structured data table is not provided.
• Row count and column-level documentation are absent; data semantics must be inferred from the narrative.
• Due to assay heterogeneity mentioned in the description, direct quantitative synthesis of results was not performed.

Provenance

Source

figshare admin karger

Collection Method

Systematic literature review of MEDLINE, EMBASE, and Web of Science.

Time Range

January 1995 to March 2025

Freshness

Last updated 2026-04-21 05:55:40